...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Thyrotrophin receptors, tumour radioiodine concentration and thyroglobulin secretion in differentiated thyroid cancers
【24h】

Thyrotrophin receptors, tumour radioiodine concentration and thyroglobulin secretion in differentiated thyroid cancers

机译：分化型甲状腺癌中的促甲状腺素受体，肿瘤放射性碘浓度和甲状腺球蛋白分泌

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tumour radioiodine concentration has been compared with serum thyroglobulin (Tg) and, in a few cases, with tumour complement of thyrotrophin receptors in patients with differentiated thyroid carcinoma. All tumours examined possessed TSH receptors. In most the complement was similar to that of normal thyroid tissue although all but one of the tumours had no detectable 131I concentration in vivo even with excess TSH stimulation. Elevated serum Tg (patient taking T4 in suppressive dose) was generally associated with tumours which had 131I concentrating function when stimulated by excess TSH. Some patients, however, had high serum Tg concentration but only low or indetectable tumour 131I uptake. We conclude that (a) measurement of tumour TSH receptor complement is unlikely to be useful in clinical management as tumours which do not significantly concentrate 131I in vivo may have a normal TSH receptor complement and (b) the capacity to secrete Tg is usually associated with 131I concentration but quantitatively the relationship varies considerably between tumours.
机译：已将肿瘤放射性碘浓度与血清甲状腺球蛋白（Tg）进行了比较，在少数情况下，与分化型甲状腺癌患者的甲状腺促甲状腺素受体的肿瘤补体进行了比较。检查的所有肿瘤均具有TSH受体。在大多数情况下，补体与正常甲状腺组织相似，尽管除了其中一个肿瘤以外，所有肿瘤在体内都没有检测到131I浓度，即使有过量的TSH刺激也是如此。血清Tg升高（患者以抑制剂量服用T4）通常与受过量TSH刺激而具有131I浓缩功能的肿瘤有关。但是，有些患者的血清Tg浓度较高，但仅摄取少量或检测不到的131I肿瘤。我们得出的结论是：（a）肿瘤TSH受体补体的测量不太可能在临床管理中使用，因为体内未显着浓缩131I的肿瘤可能具有正常的TSH受体补体，并且（b）分泌Tg的能力通常与131I浓度不同，但肿瘤之间的关系在数量上差异很大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号